Case Report: PTHrP Related Hypercalcemia in Diffuse Large B-cell Lymphoma

Ankita Mehta, MD
Thomas Jefferson University Hospital, ankita.mehta@jefferson.edu

Evan Caruso, MD
Thomas Jefferson University, evan.caruso@jefferson.edu

Follow this and additional works at: http://jdc.jefferson.edu/tmf
Part of the Internal Medicine Commons, and the Oncology Commons
Let us know how access to this document benefits you

Recommended Citation
DOI: https://doi.org/10.29046/TME:017.1.011
Available at: http://jdc.jefferson.edu/tmf/vol17/iss1/10

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in The Medicine Forum by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Case Report: PTHrP Related Hypercalcemia in Diffuse Large B-cell Lymphoma

Ankita Mehta, MD, and Evan Caruso, MD

INTRODUCTION

Hypercalcemia is commonly associated with solid tumor malignancies, but less often with hematologic malignancies. When present in hematologic malignancies, hypercalcemia is often secondary to overproduction of Vitamin D from the tumor cells. Very few cases with parathyroid hormone related peptide (PTHrP) induced hypercalcemia in B-cell lymphomas have been reported. Here we present a 44 year old male with a history of chronic lymphocytic leukemia who presented with hypercalcemia and an elevated PTHrP, found to have a transformation to Diffuse Large B-cell Lymphoma (DLBCL).

CASE PRESENTATION

A 44 year old male with chronic lymphocytic leukemia (CLL) status post four cycles of rituximab, cyclophosphamide, vincristine and prednisone and currently carboplatin, and etoposide. His calcium has remained stable since, and he returned his calcium to normal range and relieved his symptoms. His calcium between 11 and 12 mg/dL, but did not normalize fluids and re-dosing of pamidronate, which stabilized his lymphoma. His hypercalcemia was again treated with fluids, calcitriol, and Vitamin D levels, and elevated PTHrP at 57 pmol/L. Upon further investigation, including a bone marrow biopsy, it was determined that the CLL had transformed to a more aggressive subtype, diffuse large B-cell Lymphoma. He did not complain of any abdominal pain, but did complain of diffuse bone pain. CT of the chest, abdomen, and pelvis showed adenopathy throughout with some mild sphenomegaly. The patient's hypercalcemia was treated with fluids, calcitriol, and pamidronate with improvement in symptoms and normalization of calcium levels. His DLBCL was treated with a cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). However, his neutrophil count did not recover as expected and his calcium began to increase again two weeks after initial treatment. A repeat bone marrow biopsy was consistent with refractory B-cell lymphoma. His hypercalcemia was again treated with fluids and re-dosing of pamidronate, which stabilized his calcium between 11 and 12 mg/dL, but did not normalize it. He began experiencing fatigue and bone pain again. He was started on dexamethasone 6 mg every 6 hours which returned his calcium to normal range and relieved his symptoms. His calcium has remained stable since, and he is to undergo therapy with bendamustine, ofatumumab, carboplatin, and etoposide.

DISCUSSION

Though hypercalcemia is commonly seen in adult T cell lymphomas/leukemia and solid tumors via excess production of PTHrP, less than 10% of patients with non Hodgkin’s B-cell lymphomas develop hypercalcemia. The hypercalcemia seen in B cell lymphomas is usually due to non PTHrP related mechanisms. There are various explanations of the pathophysiology for hypercalcemia in hematologic malignancies. Most of the case studies that have reported B-cell lymphomas with hypercalcemia secondary to PTHrP hypersecretion are high grade lymphomas. Our patient’s case supports these findings, as he too had a Richter’s transformation on bone marrow biopsy. Correlation between the concentration of the protein and the degree of hypercalcemia suggests a causal relationship. Numerous case reports have shown that hypercalcemia in B cell lymphoma is a poor prognostic factor. In Majmudar’s article, of the eight patients he reported, median survival time from developing hypercalcemia was nine months.

KEY POINTS

The mechanisms of hypercalcemia in hematologic malignancies are multifactorial and yet to be fully understood. However, it is important to evaluate the cause and promptly treat the hypercalcemia. It is imperative to determine calcium levels given that it is a prognostic indicator and of clinical significance. PTHrP mediated hypercalcemia is rare in B cell lymphomas, but has been reported in high grade and transformed disease and should be considered in the evaluation of hypercalcemia in this subset of patients.

REFERENCES